A novel sulidac derivative protects retinal cells and the heart from oxidative damage

Oxidative damage is believed to play a significant in the etiology of many age related diseases. We have previously reported that sulindac, a known cyclooxygenase (COX) inhibitor and FDA approved anti-inflammatory drug, can initiate a pharmacological preconditioning response, similar to ischemic preconditioning (IPC). The current project aims to understand the mechanism of protection offered by MCI-100, a derivative of sulindac and sulindac against oxidative damage using RNA sequencing

氧化损伤被认为在多种年龄相关性疾病的病因学中发挥关键作用。我们既往研究表明，舒林酸——一种经典的环氧合酶（cyclooxygenase, COX）抑制剂，同时是获美国食品药品监督管理局（FDA）批准的抗炎药物——可诱发与缺血预适应（ischemic preconditioning, IPC）相似的药物预适应应答。本研究旨在通过RNA测序技术，解析舒林酸衍生物MCI-100与舒林酸针对氧化损伤的保护作用机制。